ArticlePharmacoEconomics2007
Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters.
Article in PharmacoEconomics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.PharmacoEconomics · 2013Pooled it
- Reducing depression in older home care clients: design of a prospective study of a nurse-led interprofessional mental health promotion intervention.BMC geriatrics · 2011Trial
- Article
- Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature.PharmacoEconomics · 2024Review
- Design and rationale of the Botswana Smoking Abstinence Reinforcement Trial: a protocol for a stepped-wedge cluster randomized trial.Implementation science communications · 2024Article
- Net-benefit regression with censored cost-effectiveness data from randomized or observational studies.Statistics in medicine · 2022Article
- Cost-effectiveness of physical activity intervention in children - results based on the Physical Activity and Nutrition in Children (PANIC) study.The international journal of behavioral nutrition and physical activity · 2021Article
- The cost-effectiveness of a culturally tailored parenting program: estimating the value of multiple outcomes.Cost effectiveness and resource allocation : C/E · 2021Article
- A cost-effectiveness analysis of dialectical behaviour therapy for treating individuals with borderline personality disorder in the community.Irish journal of medical science · 2020Article
- Article
- Better informing decision making with multiple outcomes cost-effectiveness analysis under uncertainty in cost-disutility space.PloS one · 2015Article
- Heterogeneity in cost-effectiveness of lifestyle counseling for metabolic syndrome risk groups -primary care patients in Sweden.Cost effectiveness and resource allocation : C/E · 2013Article
- Applying the net-benefit framework for assessing cost-effectiveness of interventions towards universal health coverage.Cost effectiveness and resource allocation : C/E · 2012Article
- Article
- Individualized cost-effectiveness analysis.PLoS medicine · 2011Article
- Sensitivity analysis in cost-effectiveness studies: from guidelines to practice.PharmacoEconomics · 2011Review
- Article
- Mental health economics: the Netherlands experience.Global & regional health technology assessmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The principal aim of this article is to share lessons learned by the authors while conducting economic evaluations, using clinical trial data, of mental health interventions. These lessons are quite general and have clear relevance for pharmacoeconomic studies. In addition, we explore how net benefit regression can be used to enhance consideration of key issues when conducting an economic evaluation based on clinical trial data. The first study we discuss found that cost-effectiveness results varied markedly based on the choice of both the patient outcome and the willingness to pay for more of that outcome. The importance of willingness to pay was also highlighted in the results from the second study. Even with a set willingness-to-pay value, most of the time the probability that the new treatment was cost effective was not 100%. In the third study, the cost effectiveness of the new treatment varied by patient characteristics. These observations have important implications for pharmacoeconomic studies. Namely, analysts must carefully consider choice of patient outcome, willingness to pay, patient heterogeneity and the statistical uncertainty inherent in the data. Net benefit regression is a useful technique for exploring these crucial issues when undertaking an economic evaluation using patient-level data on both costs and effects.
Indexed as
Identifiers
17887803What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.